For instance, 200 μM of zoledronic acid, a medication used to treat various bone diseases, inhibits G6PD activity in bladder tumor cells by interfering with the Ras signaling pathway, which is known to regulate G6PD, leading to decreased G6PD expression [157]. This evidence concerns the gene G6PD and urinary bladder neoplasm.